Artelo Biosciences, Inc. Form 8-K Filing

This Form 8-K filing by Artelo Biosciences, Inc. details a one-for-three reverse stock split effective March 10, 2026. This action reduced the number of outstanding common shares and authorized shares. The filing also incorporates by reference the company's audited financial statements for the fiscal years ending December 31, 2024, and 2025. These statements, found in Exhibit 99.1, present the company's financial position and results of operations. Key financial highlights include a net loss of $12,879 thousand for the year ended December 31, 2025, and a decrease in cash and cash equivalents to $600 thousand from $2,338 thousand in the prior year. The company experienced significant increases in accounts payable and accrued liabilities, as well as convertible notes, contributing to a substantial increase in total liabilities. The company continues to operate at a loss and plans to seek additional funding through equity or debt offerings to continue operations, raising substantial doubt about its ability to continue as a going concern.